CDK6 and myelodysplastic syndrome: MiR-124 is involved in MDS pathogenesis via targeting the cyclin-dependent kinase 6 (CDK6) gene and was upregulated in response to epigenetic treatments, azacytidine, or the histone deacetylase inhibitor panobinostat in peripheral blood and bone marrow mononuclear cells [87,88].